Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Cell(2022)10.1016/j.cell.2022.12.018Source: DataRank Database

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants is a research paper published in Cell (2022). On theSindex it has a DataRank of 0. It has been cited 948 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access948 citations

Download PDF

Cite:

Linked data & code

cellosaurus pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 87.42)OA: hybridTopics (38)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Sho Iketani ORCID,Zhiteng Li ORCID,Liyuan Liu ORCID,Yicheng Guo ORCID,Yiming Huang ORCID

Live enrichment

PubMed:36580913 PMC:PMC9747694 OpenAlex:https://openalex.org/W4311359167

NIAID NIH HHS

Grant: 75N93019C00051

NIAID NIH HHS

Grant: T32 AI100852

NIAID NIH HHS

Grant: UM1 AI069470

FWCI

87.42

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttp://www.cell.com/article/S0092867422015318/pdf

publisherhttp://www.cell.com/article/S0092867422015318/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867422015318?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867422015318?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cell.2022.12.018

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses

MeSH Terms

COVID-19SARS-CoV-2COVID-19 VaccinesAntibodies, MonoclonalAntibodies, ViralHumansImmune EvasionAntibodies, Neutralizing

Keywords

BiologyVirologyMonoclonal antibodyAntibodyNeutralizationTiterSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Dominance (genetics)Coronavirus disease 2019 (COVID-19)Spike ProteinPopulationVirusImmunologyGeneticsGeneInfectious disease (medical specialty)DiseaseNeutralizing Monoclonal AntibodyMrna VaccineReceptor Binding AffinityAntibody EvasionCovid-19Sars-cov-2Bq.1Bq.1.1XbbXbb.1

Sustainable Development Goals

SDG 0: Good health and well-being